Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study

Trial Profile

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. A Prospective, Mono-center, Placebo- and Active Treatment-controlled, Randomized, Cross Over Study

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2014

At a glance

  • Drugs Clopidogrel (Primary) ; Lansoprazole (Primary) ; Aspirin; Prasugrel
  • Indications Cardiovascular disorders; Coronary artery disease; Embolism and thrombosis; Gastrointestinal disorders
  • Focus Pharmacodynamics; Pharmacogenomic
  • Acronyms DOSAPI
  • Most Recent Events

    • 03 Jul 2012 Actual patient number (82) added as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 03 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top